Brief: Vigil Neuroscience Announces Update On Its Small Molecule TREM2 Agonist Program

Vigil Neuroscience

08/09/2023 21:33

Sept 8 (Reuters) - Vigil Neuroscience Inc  VIGL.O :
    * VIGIL NEUROSCIENCE ANNOUNCES UPDATE ON ITS SMALL MOLECULE
TREM2
AGONIST PROGRAM
    * VIGIL NEUROSCIENCE INC - PHASE 1 DOSING EXPECTED TO
COMMENCE IN
OCTOBER 2023; NO ANTICIPATED DELAYS IN CURRENT CLINICAL
DEVELOPMENT PLANS
    * VIGIL NEUROSCIENCE INC - IND FOR VG-3927 NOW OPEN
    * VIGIL NEUROSCIENCE INC - COMPANY EXPECTS TO RECEIVE
ADDITIONAL
DETAILS FROM FDA WITHIN NEXT 30 DAYS
    * VIGIL NEUROSCIENCE INC - WILL WORK CLOSELY WITH FDA TO
ADDRESS
PARTIAL CLINICAL HOLD

Source text for Eikon:  ID:nGNX9wlYJx 
Further company coverage:  VIGL.O 

 ((Reuters.Briefs@thomsonreuters.com;))